Pharmacological interventions for primary sclerosing cholangitis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 4, 2017, Pages

  Saffioti, Francesca ^a,b   Gurusamy, Kurinchi Selvan ^a   Hawkins, Neil ^c   Toon, Clare D ^d   Tsochatzis, Emmanuel ^a   Davidson, Brian R ^a   Thorburn, Douglas ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MESSINA   (Italy)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d WEST SUSSEX COUNTY COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

URSODEOXYCHOLIC ACID;

BILE DUCT CARCINOMA; CLINICAL OUTCOME; FOLLOW UP; HUMAN; LIVER TRANSPLANTATION; MORTALITY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

EID: 85018510548     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011343.pub2     Document Type: Review

References (177)

1. Allison MC, Burroughs AK, Noone P, Summerfield JA. Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study. Journal of Hepatology 1986;3(1):118-22. 5324937
2. Bansi D, Christie J, Fleming K, Chapman R. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a randomised double-blind placebo-controlled trial. Gastroenterology 1996;110(4):A1146. 5324939
3. Bansi D, Christie J, Fleming K, Chapman R. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a randomised double-blind, placebo-controlled trial. Gut 1996;38(Suppl 1):A54. 5324940
4. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16(3):707-14. 5324943
5. Beuers U, Spengler U, Kruis W, Aydemir Û, Heldwein W, Weinzierl M, et al. Effect of ursodeoxycholic acid in primary sclerosing cholangitis: a controlled trial [abstract]. Hepatology 1991;14(4 Pt 2):64a. 5324942
6. Spengler U, Beuers U, Kruis W, et al. Ursodeoxycholic acid in primary sclerosing cholangitis. Bile Acids and the Hepatobiliary System From Basic Science to Clinical Practice Proceedings of Falk Symposium 68th Held in Basel, Switzerland, October 12-14, 1992.. 1993:316-22. 5324944
7. Beuers U, Cullen SN, Fleming K, Rust C, Chapman RW. Tolerance and efficacy of a high-dose treatment with urosodeoxycholic acid in primary sclerosing cholangitis. A double-blind randomised, placebo-controlled dose-finding study. Zeitschrift fur Gastroenterologie 2006;44(8):760. 5324946
8. Cullen SN, Rust C, Fleming K, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. Journal of Hepatology 2006;44(2 Suppl):S235-6. 5324947
9. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. Journal of Hepatology 2008;48(5):792-800. 5324948
10. De Maria N, Colantoni A, Rosenbloom E, Van Thiel DH. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 1996;43(12):1472-9. 5324950
11. Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40(6):1379-86. 5324952
12. Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, Spek M, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. Journal of Clinical Gastroenterology 2008;42(5):522-6. 5324954
13. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994;106(2):494-9. 5324956
14. LaRusso N, Wiesner R, Ludwig J, MacCarty R, Beaver S, Zinsmeister A, et al. Randomized trial of penicillamine in primary sclerosing cholangitis. Hepatology 1986;6(5):1205. 5324958
15. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988;95(4):1036-42. 5324959
16. Hilscher M, Tabibian JH, Enders FB, Carey EJ, Lindor KD. Long-term follow-up of a multicenter, randomized controlled trial of ursodeoxycholic acid in primary sclerosing cholangitis. Hepatology 2015;62:509A. 5324961
17. Lindor KD. A randomized trial of ursodeoxycholic acid (UDCA) in the treatment of primary sclerosing cholangitis (PSC). Gastroenterology 1996;110(4):A1252. 5324962
18. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. The New England Journal of Medicine 1997;336(10):691-5. 5324963
19. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124(4):889-93. 5324964
20. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. The American Journal of Gastroenterology 2011;106(9):1638-45. 5324966
21. Lindor KD, Enders FB, Schmoll JA, Hoskin TL, Jorgensen RL, Petz JL. Randomized, double-blind controlled trial of high-dose ursodeoxycholic acid (UCDA) for primary sclerosing cholangitis (PSC). Hepatology 2008;48(4Suppl):378a. 5324967
22. Lindor KD, Kowdley KV, Luketic VAC, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50(3):808-14. 5324968
23. Sinakos E, Marshall HU, Kowdley KV, Befler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression. Hepatology 2010;52:197-203. 5324969
24. Lo SK, Herrmann R, Chapman RW, Fleming KA, Shearman J, Cusick P, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: a double-blind placebo controlled trial. Hepatology 1992;16(2 Pt 2):92a. 5324971
25. Mitchell S, Bansi D, Hunt N, Christie J, Fleming K, Chapman R. High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): results after two years of a randomised double-blind, placebo-controlled trial. Gastroenterology 1997;112(4):A1335. 5324973
26. Mitchell SA, Bansi D, Hunt N, Christie J, Fleming K, Chapman R. High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): results after two years of a randomised double-blind, placebo-controlled trial. Gut 1997;40(Suppl 1):A29. 5324974
27. Mitchell SA, Bansi DS, Hunt N, Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121(4):900-7. 5324975
28. Olsson R, Broome U, Danielsson A, Hagerstrand I, Jarnerot G, Loof L, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995;108(4):1199-203. 5324977
29. Lindstrom L, Boberg KM, Friis-Liby I, Hultcrantz RW, Bergquist A. A reduction in alkaline phosphatase levels is associated to improved prognosis in primary sclerosing cholangitis: a 14 year follow up of the Scandinavian ursodeoxycholic acid trial. Hepatology 2012;56:247a. 5324979
30. Lindstrom L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Alimentary Pharmacology and Therapeutics 2012;35(4):451-7. 5324980
31. Olsson R, Boberg KM, De Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129(5):1464-72. 5324981
32. Olsson RG, Boberg KM, Schaffalitzky de Muckadel O, Lindgren S, Hultcrantz R, Folvik G, et al. Five-year treatment with high-dose UDCA in PSC. Journal of Hepatology 2004;40(Suppl 1):161. 5324982
33. Rahimpour S, Nasiri-Toosi M, Khalili H, Daryani NE, Taromlou MKN, Azizi Z. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. Journal of Gastrointestinal and Liver Diseases 2016;25(4):457-64. 5324984
34. Rasmussen HH, Tage-Jensen U, Vyberg M, Schlichting P, Schaffalitzky de Mucadell O, Bonnevie O. Methotrexate for treatment of primary sclerosing cholangitis. Journal of Hepatology 1998;28(1 Suppl 1):128. 5324986
35. Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993;34(2):242-6. 5324988
36. Wiesner RH, Steiner B, LaRusso NF, Lindor KD, Baldus WP. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis. Hepatology 1991; Vol. 14, issue 4 Pt 2:63a. 5324989
37. Sterlin RK, Salvatori JJ, Luketic VA, Sanyal AJ, Stravitz RT, Fulcher AS, et al. A prospective, randomized controlled pilot study of ursodeoxycholic acid (UDCA) combined with mycophenolate mofetil (MMF) in the treatment of primary sclerosing cholangitis. Hepatology 2003;38(4 Suppl 1):204a. 5324991
38. Sterling RK, Salvatori JJ, Luketic VA, Sanyal AJ, Fulcher AS, Stravitz RT, et al. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics 2004;20(9):943-9. 5324992
39. Stiehl A, Raedsch R, Rudolph G, Theilmann L. Treatment of primary sclerosing cholangitis with ursodeoxycholic acid: first results of a controlled study. Hepatology 1989;10(4):602. 5324994
40. Tabibian JH, Lindor KD. Long-term outcomes following a randomized study of oral antibiotics in primary sclerosing cholangitis. Gastroenterology 2016;150(4 Suppl 1):S1069-S70. 5324996
41. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Alimentary Pharmacology and Therapeutics 2013;37(6):604-12. 5324997
42. Trauner MH, Fickert P, Hirschfield G, Denk G, Altorjay I, Marschall HU, et al. Norursodeoxycholic acid (NORUDCA) improves cholestasis in primary sclerosing cholangitis (PSC) independent of ursodeoxycholic acid (UDCA) pre-treatment and response. Hepatology 2016;64(Suppl 1):111A. 5324999
43. Beuers U, Sackmann FM. Treatment of primary sclerosing cholangitis: drug, endoscopic, combined or no treatment at all?. Zeitschrift für Gastroenterologie 1998;36(2):189-91. 5325001
44. Chapman RW. High-dose ursodeoxycholic acid in the management of primary sclerosing cholangitis. Bile Acid Biology and Its Therapeutic Implications 2005;141:230-41. 5325003
45. Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?. Hepatology 2009;50(3):671-3. 5325005
46. Eisenburg J. Primary sclerosing cholangitis. Ursodeoxycholic acid is without clinical effect. Fortschritte der Medizin 1997;115(18):7-8. 5325007
47. Fromm H. New treatment for primary sclerosing cholangitis: promising results with ursodiol. Gastroenterology 1992;103(1):343-4. 5325009
48. Goldberg E, Gerdes H. Primary sclerosing cholangitis: is medical therapy on the way?. Gastroenterology 1992;102(2):729-31. 5325011
49. Gross JB. Promises, promises: ursodeoxycholic acid for primary sclerosing cholangitis. Gastroenterology 1993;104(3):941-3. 5325013
50. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. The American Journal of Gastroenterology 2001;96(5):1558-62. 5325015
51. Hay JE, Malinchoc M, Dickson ER. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. Journal of Hepatology 2001;34(2):292-8. 5325017
52. Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M, et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics 2011;34(10):1185-92. 5325019
53. Kuiper EMM, van Erpedum KJ, Beuers U, Hansen BE, Thio HB, de Man RA, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52(4):1334-40. 5325021
54. Kurihara T, Maeda A, Shigemoto M, Yamashita K, Kamatani N. Efficacy of bezafibrate in a patient with primary sclerosing cholangitis. Journal of Gastroenterology 2003;38(3):300-1. 5325023
55. Lankarani KB. Use of mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Journal of Clinical Gastroenterology 2003;36(1):86. 5325025
56. Lankarani KB. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Alimentary Pharmacology & Therapeutics 2005;21(10):1279-80. 5325027
57. Lindor K. Long-term experience with ursodeoxycholic acid for patients with primary biliary cirrhosis and primary sclerosing cholangitis. International Falk Workshop Bile Acids in Liver Diseases 1995:141-5. 5325029
58. Lindor KD. Dose effect of ursodeoxycholic acid used in the treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Bile Acid Biology and Its Therapeutic Implications 2005;141:225-9. 5325031
59. Lindor KD. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Bile Acid Biology and Therapeutic Actions. Vol. 165, Dordrecht: Springer, 2009:255-8. 5325033
60. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007;45(3):666-74. 5325035
61. Silveira MG, Lindor KD. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Journal of Hepatology 2008;48(5):692-4. 5325037
62. Spengler U, Beuers U, Kruis W, Aydemir Û, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid in primary sclerosing cholangitis. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Proceedings of Falk Symposium 68 1993:316-22. 5325039
63. Stiehl A, Raedsch R. Treatment of primary sclerosing cholangitis with ursodeoxycholic acid. Zeitschrift fur Gastroenterologie - Verhandlungsband 1989;24:136. 5325041
64. Stiehl A, Raedsch R. [Treatment of primary sclerosing cholangitis with ursodeoxycholic acid]. Z Gastroenterol Verh 1989;24:136. 5325043
65. Stiehl A. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology. Supplement 1994;204:59-61. 5325045
66. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. Journal of Hepatology 1994;20(1):57-64. 5325047
67. Stiehl L, Rudolph G, Raedsch R, Stiehl A. Effects of ursodeoxycholic acid in patients with primary sclerosing cholangitis. Bile Acids as Therapeutic Agents. From Basic Science to Clinical Practice. Proceedings of Falk Symposium 58 1991, (37):305-7. 5325048
68. Stiehl A. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Italian Journal of Gastroenterology 1996;28(3):178-80. 5325050
69. Tabibian N. Rifampin as antipruritic agent in primary sclerosing cholangitis. American Journal of Gastroenterology 1989;84(3):340. 5325052
70. Tada S, Ebinuma H, Saito H, Hibi T. Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis. Journal of Gastroenterology 2006;41(4):388-9. 5325054
71. ter Borg PC, Os E, Broek WW, Hansen BE, Buuren HR. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterology 2004;4:13. 5325056
72. Triantos CK, Koukias N, Nikolopoulou V, Burroughs AK. Ursodeoxycholic acid in primary sclerosing cholangitis. Alimentary Pharmacology & Therapeutics 2012;35(5):622-3. 5325058
73. van de Meeberg PC, Wolfhagen FH, Van Berge-Henegouwen GP, Salemans JM, Tangerman A, van Buuren HR, et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. Journal of Hepatology 1996;25(6):887-94. 5325060
74. Hoogstraten HJ, Wolfhagen FH, Meeberg PC, Kuiper H, Nix GA, Becx MC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. Journal of Hepatology 1998;29(3):417-23. 5325062
75. Hoogstraten HJF, Meeberg PC, Wolfhagen FHJ, Kuiper H, Hop WCJ, Berge-Henegouwen GP, et al. Ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis (PSC): results of a 2-year randomized controlled trial evaluating single versus multiple daily doses. Hepatology 1997;26(4 Pt 2):401a. 5325063
76. Hoogstraten HJF, Wolfhagen FJH, Meeberg PC, Buuren HR, Berge Henegouwen GP, Schalm SW. Single versus three times daily ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis (PSC): results of a randomized controlled trial. European Journal of Gastroenterology and Hepatology 1996;8(Suppl 12):A 7. 5325064
77. Vleggaar FP, van Hoogstraten HJF, Boland GJ, van Steenbergen W, van Hattum J, Henegouwen GPV, et al. Treatment with budesonide or prednisone in combination with ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): a randomized controlled pilot study. Hepatology 1998;28(4):647A. 5325065
78. van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, Kuiper H, Nix GA, Becx MC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. Journal of Hepatology 1998;29(3):417-23. 5325066
79. van Hoogstraten HJF, Wolfhagen FJH, van de Meeberg PC, van Buuren HR, Henegouwen GPB, Schalm SW. Single versus three times daily ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis (PSC): results of a randomized controlled trial. Gastroenterology 1996;110(4):A1352. 5325067
80. van Hoogstraten HJF, van de Meeberg PC, Wolfhagen FHJ, Kuiper H, Hop WCJ, van Berge Henegouwen GP, et al. Ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis (PSC): results of a 2-year randomized controlled trial evaluating single versus multiple daily doses. Hepatology 1997;26(4):1089. 5325068
81. Hoogstraten HJ, Vleggaar FP, Boland GJ, Steenbergen W, Griffioen P, Hop WC, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. The American Journal of Gastroenterology 2000;95(8):2015-22. 5325070
82. van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. American Journal of Gastroenterology 2000;95(8):2015-22. 5325071
83. Vanthiel DH, Wright HI, Gavaler JS. Ursodeoxycholic acid (UDCA) therapy for primary sclerosing cholangitis (PSC) - preliminary report of a randomized controlled trial. Hepatology 1992;16(4):A62. 5325073
84. Villamil AG, Bandi JC, Galdame OA, Gerona S, Gadano AC. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. The American Journal of Medicine 2005;118(10):1160-3. 5325075
85. Vleggaar FP, Buuren HR, Berge Henegouwen GP, Hop WC, Erpecum KJ. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. European Journal of Gastroenterology and Hepatology 2001;13(2):171-5. 5325077
86. Vleggaar FP, Van Buuren HR, Henegouwen GPV, Van Erpecum KJ. No beneficial effects of transdermal nicotine in primary sclerosing cholangitis (PSC): results of a randomized double-blind cross-over study. Hepatology 1999;30(4):563A. 5325078
87. Vleggaar F, Monkelbaan J, Van Erpecum K. No beneficial effects of probiotics in primary sclerosing cholarigitis (PSC): a randomized placebo-controlled cross-over study. Gastroenterology 2007;132(4):A767. 5325080
88. Vleggaar FP, Monkelbaan JF, Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. European Journal of Gastroenterology and Hepatology 2008;20(7):688-92. 5325081
89. Vleggaar FP, Monkelbaan JF, van Erpecum KJ. No beneficial effects of probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover study. European Journal of Gastroenterology and Hepatology 2008;20(7):A67. 5325082
90. Wagner A. Azathioprine treatment in primary sclerosing cholangitis. Lancet 1971;2(7725):663-4. 5325084
91. Anonymous . Primary sclerosing cholangitis. To slow progression and reduce carcinoma risk. MMW Fortschritte der Medizin 2006;148(24):42-3. 5325086
92. Randomised trial of low dose, medium dose and high dose ursodeoxycholic acid with placebo in primary sclerosing cholangitis. http://isrctn.com/ISRCTN16531030 (accessed 5 July 2015). 5325088
93. Trial of high-dose urso in primary sclerosing cholangitis. http://clinicaltrials.gov/show/NCT00059202 (accessed 5 July 2015). 5325090
94. Randomized double-blind placebo-controlled trial to evaluate the efficacy of N-acetylcystein in patients with chronic pancreatitis and primary sclerosing cholangitis.. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004170-26 (accessed 5 July 2015). 5325092
95. A phase 3, open-label, randomized, prospective clinical trial evaluating the efficacy of stratified treatment with ursodeoxycholic acid (UDCA) in preventing hepatobiliary and colorectal malignancy in surveillance patients with primary sclerosing cholangitis (PSC). https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003310-24/SE (accessed 22 February 2017). 5325094
96. A phase 2, randomized, double blind, placebo controlled, parallel group, multiple center study to evaluate the safety, tolerability, and efficacy of NGM282 administered for 12 weeks in patients with primary sclerosing cholangitis (PSC). https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003392-30/GB/ (accessed 22 February 2017). 5325096
97. Simtuzumab (GS-6624) in the prevention of progression of liver fibrosis in subjects with primary sclerosing cholangitis (PSC). http://clinicaltrials.gov/show/NCT01672853 (accessed 5 July 2015). 5325098
98. Mitomycin C therapy for patients with primary sclerosing cholangitis. http://clinicaltrials.gov/show/NCT01688024 (accessed 5 July 2015). 5325100
99. Norursodeoxycholic acid in the treatment of primary sclerosing cholangitis NUC-3. http://clinicaltrials.gov/show/NCT01755507 (accessed 5 July 2015). 5325102
100. Obeticholic acid (OCA) in primary sclerosing cholangitis (PSC). https://clinicaltrials.gov/show/NCT02177136 2015 (accessed 30 June 2015). 5325104
101. Phase 2 study of NGM282 in patients with primary sclerosing cholangitis. https://clinicaltrials.gov/ct2/show/NCT02704364 (accessed 22 February 2017). 5325106
102. Safety, tolerability, and efficacy of GS9674 in adults with primary sclerosing cholangitis without cirrhosis (PSCphase 2). https://clinicaltrials.gov/ct2/show/NCT02943460 (accessed 22 February 2017). 5325108
103. Efficacy and safety of vedolizumab intravenous (IV) in the treatment of primary sclerosing cholangitis in subjects with underlying inflammatory bowel disease. https://clinicaltrials.gov/ct2/show/NCT03035058 (accessed 22 February 2017). 5325110
104. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. Journal of Hepatology 2012;56(5):1181-8.
105. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58(6):2045-55.
106. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods 2012;3(2):161-76.
107. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PloS One 2013;8(10):e76654.
108. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. Spirit 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200-7.
109. Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World Journal of Gastroenterology 2008;14(21):3350-9.
110. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51(2):660-78.
111. Del Re AC, Spielmans GI, Flückiger C, Wampold BE. Efficacy of new generation antidepressants: differences seem illusory. PLoS One 2013;8(6):e63509.
112. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
113. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
114. Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment, September 2011 (last updated April 2012). www.nicedsu.org.uk/TSD3%20Heterogeneity.final%20report.08.05.12.pdf (accessed 27 March 2014).
115. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 1: Introduction to evidence synthesis for decision making, April 2011 (last updated April 2012). www.nicedsu.org.uk/TSD1%20Introduction.final.08.05.12.pdf (accessed 27 March 2014).
116. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, August 2011 (last updated April 2014). http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf (accessed 8 October 2014).
117. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: Inconsistency in networks of evidence based on randomised controlled trials, May 2011 (last updated April 2014). http://www.nicedsu.org.uk/TSD4%20Inconsistency.final.15April2014.pdf (accessed 8 October 2014).
118. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. Journal of Hepatology 2009;51(2):237-67.
119. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
120. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Digestive Diseases and Sciences 2004;49(1):1-4.
121. EuroQol . About EQ-5D. http://www.euroqol.org/about-eq-5d.html (accessed 8 October 2014).
122. Giljaca V, Poropat G, Stimac D, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD004036.pub3]
123. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 7. Art. No.: LIVER.
124. Gores GJ, Darwish Murad S, Heimbach JK, Rosen CB. Liver transplantation for perihilar cholangiocarcinoma. Digestive Diseases 2013;31(1):126-9.
125. Gross JB Jr, Ludwig J, Wiesner RH, McCall JT, LaRusso NF. Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology 1985;89(2):272-8.
126. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
127. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
128. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research Synthesis Methods 2012;3(2):98-110.
129. International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines. Vol. 1, Pennsylvania, USA: Barnett International/PAREXEL, 1997.
130. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology 2014;14(1):120.
131. Jay CL, Lyuksemburg V, Ladner DP, Wang E, Caicedo JC, Holl JL, et al. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. Annals of Surgery 2011;253(2):259-64.
132. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
133. Klingenberg SL, Chen W. D-penicillamine for primary sclerosing cholangitis. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004182.pub3]
134. Klose J, Klose MA, Metz C, Lehner F, Manns MP, Klempnauer J, et al. Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era. Langenbecks Archives of Surgery 2014;399(8):1021-9.
135. Koro NS, Alkaade S. Role of endoscopy in primary sclerosing cholangitis. Current Gastroenterology Reports 2013;15(12):361.
136. Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics 2013;45(6):670-5.
137. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006;101(474):447-59.
138. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3]
139. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
140. Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308(12):1246-53.
141. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
142. NCBI . Cholangitis, Sclerosing. http://www.ncbi.nlm.nih.gov/mesh/68015209 (accessed 10 June 2014).
143. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
144. Novak K, Swain MG. Role of methotrexate in the treatment of chronic cholestatic disorders. Clinics in Liver Disease 2008;12(1):81-96.
145. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Seminars in Liver Disease 2006;26(1):3-21.
146. Members of OpenBUGS Project Management Group. OpenBUGS. Version 3.2.3. Members of OpenBUGS Project Management Group, 2014.
147. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36(3):525-31.
148. Pawlik TM, Olbrecht VA, Pitt HA, Gleisner AL, Choti MA, Schulick RD, et al. Primary sclerosing cholangitis: role of extrahepatic biliary resection. Journal of the American College of Surgeons 2008;206(5):822-30.
149. Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World Journal of Gastroenterology 2009;15(14):1677-89.
150. Ponsioen CY, Chapman RW, Chazouilleres O, Hirschfield GM, Karlsen TH, Lohse AW, et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an international PSC study group consensus process. Hepatology 2016;63(4):1357-67.
151. Poropat G, Giljaca V, Stimac D, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD003626.pub2]
152. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630.
153. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
154. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
155. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71.
156. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012;3(2):80-97.
157. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment 2012;16(35):1-82.
158. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
159. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
160. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Medicine 2010;7(3):e1000251.
161. StataCorp LP. Stata/SE 14.2 for Windows[64-bit x86-64]. Version 14. College Station: StataCorp LP, 2017.
162. Stewart L. Iatrogenic biliary injuries: identification, classification, and management. Surgical Clinics of North America 2014;94(2):297-310.
163. Tabibian JH, Lindor KD. Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). Hepatology 2014;60(3):785-8.
164. Talwalkar JA, Lindor KD. Natural history and prognostic models in primary sclerosing cholangitis. Best Practice & Research: Clinical Gastroenterology 2001;15(4):563-75.
165. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. American Journal of Gastroenterology 2005;100(2):308-12.
166. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User Manual for Trial Sequential Analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. www.ctu.dk/tsa 2011:1-115.
167. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Systematic Reviews 2012;1:41.
168. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Alimentary Pharmacology & Therapeutics 2011;34(8):901-10.
169. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen. TSA version 0.9. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, 2011.
170. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818-27.
171. Valero V 3rd, Cosgrove D, Herman JM, Pawlik TM. Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Review of Gastroenterology & Hepatology 2012;6(4):481-95.
172. van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Research Synthesis Methods 2012;3(4):285-99.
173. Ware JE. SF-36® Health Survey Update. http://www.sf-36.org/tools/sf36.shtml 2014 (accessed 8 October 2014).
174. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
175. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.
176. Wunsch E, Trottier J, Milkiewicz M, Raszeja-Wyszomirska J, Hirschfield GM, Barbier O, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology 2014;60(9):31-940.
177. Yimam KK, Bowlus CL. Diagnosis and classification of primary sclerosing cholangitis. Autoimmunity Reviews 2014;13(4-5):445-50.